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Cardiovascular diseases due to atherosclerosis are the leading cause of death globally. We aimed to 
investigate the potentially altered gene and pathway expression in advanced peripheral atherosclerotic 
plaques in comparison to healthy control arteries. Gene expression analysis was performed (Illumina 
HumanHT-12 version 3 Expression BeadChip) for 68 advanced atherosclerotic plaques (15 aortic, 29 
carotid and 24 femoral plaques) and 28 controls (left internal thoracic artery (LITA)) from Tampere 
Vascular Study. Dysregulation of individual genes was compared to healthy controls and between 
plaques from different arterial beds and Ingenuity pathway analysis was conducted on genes with a fold 
change (FC) > ±1.5 and false discovery rate (FDR) < 0.05. 787 genes were significantly differentially 
expressed in atherosclerotic plaques. The most up-regulated genes were osteopontin and multiple 
MMPs, and the most down-regulated were cell death-inducing DFFA-like effector C and A (CIDEC, 
CIDEA) and apolipoprotein D (FC > 20). 156 pathways were differentially expressed in atherosclerotic 
plaques, mostly inflammation-related, especially related with leukocyte trafficking and signaling. 
In artery specific plaque analysis 50.4% of canonical pathways and 41.2% GO terms differentially 
expressed were in common for all three arterial beds. Our results confirm the inflammatory nature of 
advanced atherosclerosis and show novel pathway differences between different arterial beds.
Atherosclerosis, the most common cause for cardiovascular diseases (CVDs) is a complex disease affecting mil-
lions of people around the world1. Genetic factors, environment, lifestyle choices and the various interactions 
between these affect the development of atherosclerotic plaques and modify individuals risk for adverse CVD 
events. Development of atherosclerotic plaque modifies the arterial wall through many metabolic pathways with 
inflammation and deposition of lipids being the most crucial processes involved. There is great variability in the 
development of this disease between individuals and even though atherosclerosis has a systemic nature, there are 
differences in gene-expression in plaques occurring in different arterial beds2. Also the prevalence of calcified or 
unstable plaques often varies according to vascular region3 and the on-going processes in a plaque differ greatly 
according to the stage of the plaque4.
Atherosclerosis begins with microscopic changes in the arterial wall. Accumulation of lipoproteins5 attracts 
inflammatory cells that begin to invade the intima6,7. As the disease progresses the arterial wall gathers more lipids 
and inflammatory cells (mainly T-cells and monocytes) and a visible fatty streak forms. Although the formation 
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of a fatty streak is seen as a reversible event, it can be followed by the formation of fibrotic tissue leading to the sta-
bilization of the plaque. The vascular smooth muscle cells begin to replicate contributing to the formation of the 
atheroma and the blood flow in the artery is impaired7,8. The plaque can also gather calcium and form a hard cal-
cified plaque. The rupture or erosion of the the atherosclerotic plaque may result in a local thrombosis or release 
of distant thromboemboli, which both can have lethal consequences depending on the location of the plaque7,9.
Differentially expressed genes have been shown in various studies designed to specifically demonstrate the 
regulation of selected single genes in atherosclerosis. These studies have mostly been conducted in vivo, focusing 
on up-regulating or down-regulating selected genes, in order to find out their effect on the development and 
progression of atherosclerosis. Results show that changes in the expressions of target genes can also lead into 
the suppression of some atheroprotective qualities10,11. Previous studies have shown the inflammatory nature of 
atherosclerosis12, demonstrating the roles of different leukocytes present in atherosclerotic plaques13. Degradation 
and remodeling of the extracellular matrix14 and changes in the arterial wall15 are the most important processes 
related with atherosclerosis. Therefore, instead of single gene analysis to reveal the pathways – an unbiased whole 
genome wide pathway analyses against most recently updated gene-pathway databases are needed16–18. So far, a lot 
of data has been collected in murine and porcine models. Nevertheless, research on humans and human tissues 
is needed as genetically unaltered mice do not spontaneously develop atherosclerosis and the time frame and 
contributing risk factors differ greatly in animal models.
In ongoing Tampere Vascular Study (TVS)2 we aim to detect specific genes as well as pathways consisting of a 
set of genes differentially expressed in advanced atherosclerotic plaques compared to healthy non-atherosclerotic 
arteries (referred simply as differentially expressed). In our previous pilot work with 24 samples (6 controls and 18 
cases)2 we established genes and pathways differentially expressed in atherosclerosis, including some MMPs and 
ApoC1 and upregulated proinflammatory pathways. In this study, with a substantially larger set of samples, and 
using novel Ingenuity pathway analysis (IPA) for the pathway analysis we aimed to further analyze the pathways 
and genes differentially expressed in peripheral advanced atherosclerotic plaques in humans. We also aimed to 
find possible differences between gene sets specific for plaques formed in certain arterial beds in different parts 
of arterial network. This larger sample set has been utilized in analyzing individual genes and their role in ather-
osclerotic plaques in hypothesis based studies19–22, and this study was performed to create a more comprehensive 
description of different expression of genes and pathways in atherosclerosis.
Materials and Methods
Tampere Vascular Study. The atherosclerotic vascular samples used in this study were obtained from 
patients subjected to carotid (N = 29) and femoral (N = 24) endarterectomy or an abdominal aortic bypass 
(N = 15) procedure (i.e., aortobifemoral bypass) due to occlusive atherosclerosis. The control vessel, left internal 
thoracic artery (LITA) (N = 28) samples were obtained during coronary artery bypass surgery22–27. Each sample 
was obtained from a different individual. All open vascular surgical procedures were performed at the Division 
of Vascular Surgery and the Heart Center at Tampere University Hospital between 2006 and 200927. The study 
has been approved by the Ethics Committee of Pirkanmaa Hospital District and clinical investigation followed 
the principles of Helsinki declaration. Informed consent was acquired from patients enrolled in this study. In the 
present work the severity of atherosclerotic lesions in artery wall was histologically classified according to the 
American Heart Association classification (AHA classification I-VI)28. Demographics of the study population are 
presented in Supplementary File 1.
RNA isolation and genome wide expression analysis. The fresh tissue samples were soaked in 
RNALater solution (Ambion Inc., Austin, TX, USA) and isolated with Trizol reagent (Invitrogen, Carlsbad, CA, 
USA) and the RNAEasy Kit (Qiagen, Valencia, CA, USA). The RNA quality as well as concentration was eval-
uated spectrophotometrically (BioPhotometer, Eppendorf, Wesseling-Berzdorf, Germany). The RNA isolation 
protocol was validated with Agilent RNA 6000 Nano Kit and the RNA integrity number (RIN) and the shape of 
the electropherogram were evaluated. In all the samples with successful gene expression profiling the 260/280 
ratio was between 1.94–2.23. Over 23,000 known and candidate genes were analyzed with Illumina HumanHT-12 
version 3 Expression BeadChip (Illumina Inc.), according to manufacturer’s instructions (Illumina, San Diego, 
CA, USA). Briefly, 200 ng aliquots of total RNA from each sample were amplified to cDNA using the Ambion’s 
Illumina RNA Amplification kit according to the instructions (Ambion, Inc., Austin, TX, USA). Samples of cRNA 
(1500 ng) were hybridized to Illumina’s Expression BeadChip arrays (Illumina). Hybridized biotinylated cRNA 
was detected with 1 μ g/ml Cyanine3-streptavidine (Amersham Biosciences, Pistacataway, NJ, USA). BeadChips 
were scanned with the Illumina BeadArray Reader2. The accuracy of this array has been previously tested in our 
TVS validation study where the results of 192 differentially expressed genes were verified by RT-PCR23. The corre-
lation of expression measurements between GWE and RT-PCR methods was good (r = 0.87, y = 0.151 + 0.586x), 
and the Bland-Altman plot showed that the FCs were in agreement with these two methods, although for highly 
up- or down-regulated transcripts, GWE yielding lower absolute FC values than in LDA23.
Microarray array data analysis and multiple testing corrections. After background subtraction, raw 
intensity data were exported using the Illumina GenomeStudio software. Raw expression data were imported into 
R version 3.1.1 (http://www.r-project.org/), log2 transformed and normalized by the locally estimated scatterplot 
smoothing normalization method implemented in the R/Bioconductor package Lumi (www.bioconductor.org). 
Locally estimated scatterplot smoothing (LOESS) normalization for the data was selected because it gives the 
best accuracy in comparison with quantitative reverse transcription polymerase chain reaction data for artery 
samples23. Data quality control criteria included detection of outlier arrays based on the low number of robustly 
expressed genes and hierarchical clustering. Artery samples (n = 96: 68 plaque, 28 LITA) fulfilled all data qual-
ity control criteria, whilst 6 samples were discarded. To estimate fold changes between groups, we calculated 
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differences between medians (in log2 scale) and then back transformed the log ratios to fold changes. To ease 
the interpretation, we replaced fold-change values that are < 1 by the negative of its inverse. Statistical signifi-
cance of differences in gene expression was assessed using the nonparametric Wilcoxon signed-rank test and 
the log-transformed data. Pathway analysis of the expression data was done with QIAGEN’s Ingenuity Pathway 
Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity) for genes with FC ± 1.5 and FDR < 0.05. 
Pathways with FDR < 0.05 (Benjamini-Hochberg method29) were found to be significantly differentially 
expressed. The GO-terms were analysed using GOrilla online tool30. The Venn diagrams were done using Venny 
2.1.0 online tool31.
Results
Overall gene expression differences between atherosclerotic and atherosclerosis free arteries. 
787 of genes were significantly differentially expressed (FC > ± 3.0, FDR < 0.05) in atherosclerotic plaques in 
comparison to healthy control arteries (Supplementary File 2). Table 1 lists the most significantly differentially 
expressed genes between all atherosclerotic plaque samples versus atherosclerosis free control arteries (LITAs) 
(All vs. LITA, up- or down-regulated, FC ≥ 15, FDR < 0.05) and the corresponding FC and p-values obtained 
from comparisons between different atherosclerotic plaque groups (aortic, carotid, femoral) and LITAs. The 
single most up-regulated gene was osteopontin (SPP1/secreted phophoprotein-1) (FC = 121.9 in all atheroscle-
rotic plaques in comparison to controls). It was highly up-regulated in all analyzed atherosclerotic arterial beds 
(FC > 100) and it was the most differentially expressed gene in femoral and carotid plaques (Supplementary Files 
1 and 2).
Many of the most up-regulated genes are previously known inflammatory genes, such as CD4, CD28 and 
chemokines and chemokine receptor genes. Other significantly up-regulated gene families are the MMPs (MMP7, 
MMP9 and MMP12, FC > 28 for all when comparing all atherosclerotic plaques to controls, Table 1). In addition, 
several gene families associated with lipid transport were the most differentially expressed ones in atherosclerotic 
plaques (Table 1, Supplementary File 2). Apolipoprotein-D (ApoD) was down-regulated in all the studied arterial 
Gene symbol ACCESSION
All vs. LITA Aorta vs. LITA Carotid vs. LITA Femoralis vs LITA
FC P-value FC p-value FC p-value FC p-value
SPP1 NM_001040058.1 121.9 1.82*10−13 104.3 2.73*10−8 135.7 1.19*10−15 105.4 3.16*10−14
SPP1 NM_000582.2 109.1 1.82*10−13 90.9 2.73*10−8 113.9 1.19*10−15 99.9 3.16*10−14
MMP12 NM_002426.2 88.9 1.82*10−13 72.4 2.73*10−8 124.9 1.19*10−15 68.3 3.16*10−14
MMP9 NM_004994.2 76.1 1.82*10−13 32.0 2.73*10−8 98.8 1.19*10−15 76.9 3.16*10−14
CIDEC NM_022094.2 − 61.2 2.91*10−11 − 17.0 2.00*10−3 − 90.4 1.19*10−15 − 50.1 3.71*10−10
KIAA1881 XM_001130790.1 − 60.1 9.97*10−12 − 17.7 2.73*10−8 − 80.1 1.19*10−15 − 50.9 6.60*10−11
LOC642113 XM_936253.1 53.3 5.44*10−12 135.0 2.91*10−8 36.1 8.72*10−12 38.7 3.71*10−10
MMP7 NM_002423.3 52.5 2.21*10−13 17.8 3.93*10−8 91.8 1.19*10−15 36.2 3.16*10−14
LOC647450 XM_936518.1 52.4 5.12*10−12 153.5 2.91*10−8 47.6 8.72*10−12 32.5 2.94*10−10
LOC652493 XM_941953.1 52.1 3.55*10−12 127.7 2.91*10−8 45.2 4.17*10−12 32.1 1.82*10−10
LOC652694 XM_942302.1 47.2 3.14*10−12 129.4 2.14*10−8 46.0 2.48*10−12 22.2 1.43*10−10
MMP12 NM_002426.2 47.1 7.00*10−13 72.4 2.73*10−8 63.2 1.19*10−15 25.5 1.43*10−10
APOD NM_001647.2 − 39.7 1.24*10−10 − 1.4 3.76*10−2 − 68.1 1.19*10−15 − 43.9 3.16*10−14
APOC1 NM_001645.3 36.2 2.21*10−13 30.3 9.94*10−11 53.2 2.38*10−15 32.8 6.33*10−14
PLA2G7 NM_005084.2 29.9 2.21*10−13 12.5 5.97*10−10 43.6 1.19*10−15 28.0 3.16*10−14
MMP7 NM_002423.3 28.3 2.21*10−13 17.8 1.99*10−10 54.6 1.19*10−15 21.2 3.16*10−14
KIAA1199 NM_018689.1 25.5 1.82*10−13 31.0 4.97*10−11 26.5 1.19*10−15 19.5 3.16*10−14
CIDEA NM_001279.2 − 24.5 6.22*10−11 − 17.9 5.42*10−5 − 30.4 8.13*10−13 − 23.4 4.46*10−8
ADAMDEC1 NM_014479.2 24.2 1.82*10−13 26.1 4.97*10−11 28.5 1.19*10−15 15.0 3.16*10−14
SCARA5 NM_173833.4 − 22.8 6.16*10−13 − 3.3 1.08*10−6 − 27.0 1.19*10−15 − 23.8 3.16*10−14
ACP5 NM_001611.2 22.6 4.78*10−13 7.4 3.40*10−8 31.4 1.19*10−15 32.0 3.16*10−14
IGLL1 NM_020070.2 20.0 7.83*10−12 38.1 1.99*10−10 19.2 1.39*10−11 16.0 1.70*10−9
LOC652102 XM_941434.1 19.0 5.23*10−11 58.9 4.97*10−11 16.6 2.53*10−10 11.9 7.40*10−8
APOE NM_000041.2 17.6 7.45*10−13 15.8 1.34*10−7 27.7 2.38*10−15 16.4 3.16*10−14
PLIN NM_002666.3 − 17.3 5.87*10−11 − 12.9 4.66*10−5 − 19.0 1.44*10−12 − 18.5 1.70*10−9
ACTA1 NM_001100.3 − 16.3 7.40*10−11 − 9.3 7.02*10−7 − 19.6 2.26*10−14 − 9.2 3.86*10−7
RGS1 NM_002922.3 15.8 6.57*10−13 23.9 4.97*10−11 12.0 8.13*10−13 12.6 3.80*10−13
OLR1 NM_002543.3 15.8 3.70*10−13 20.6 5.97*10−10 15.4 5.35*10−14 17.1 1.27*10−13
MYOC NM_000261.1 − 15.2 3.05*10−13 − 11.1 2.24*10−9 − 17.8 1.19*10−15 − 10.9 6.33*10−14
Table 1.  The most significantly differentially expressed genes in All atherosclerotic plaques versus 
atherosclerosis free control arteries (LITA), (FC ≥ ± 15 and FDR < 0.05) and the corresponding FC and 
p-values from comparisons between atherosclerotic plaques from different arterial beds (abdominal aorta, 
carotid, femoral) compared to LITA. aAbbreviations: FC = fold changes (FC); FDR = False discovery rate; 
LITA = left internal thoracic artery.
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beds, whilst ApoE and ApoC1 were both significantly up-regulated in atherosclerotic plaques. ApoC1 was espe-
cially up-regulated in carotid plaques (FC = 53.2). In addition, cell death-inducing DFFA-like effector C and A 
(CIDEC, CIDEA) were significantly down-regulated in atherosclerotic plaques in comparison to control LITA. 
CIDEC and CIDEA were down-regulated in the plaques from all the studied arterial beds but there were large 
differences in the magnitude of the down-regulation (Table 1, Supplementary File 2).
Gene expression differences between plaques derived from different arterial beds. We 
also found significant differences in the gene expression patterns between plaques taken from different types 
of arteries from different vascular regions. Most significant differences were seen between plaques from aor-
tic and carotid arteries (FC > 5, FDR < 0.05) (Table 2). Especially ApoD and chemokine ligand 14, CXCL14, 
genes were down-regulated when comparing aortic to carotid artery plaque. Twenty-two genes were differentially 
expressed when comparing plaques from femoral artery to those from aorta whilst the plaques from carotid and 
femoral artery presented the most similar gene expression patterns (Table 2). The most differentially expressed 
genes between different arterial plaques (FC > 5.0, FDR < 0.05) are listed in Table 2 and more completely in 
Supplementary File 3.
Altered canonical pathways in advanced atherosclerotic plaques in comparison to LITA. 
Ingenuity pathway analysis identified 156 altered pathways between atherosclerotic plaques and healthy arteries, 
with FDR < 0.05, when analyzing genes with FC > ± 1.5. In aortic, carotid and femoral plaques 201, 143 and 190 
pathways were respectively differentially expressed, of which 121 were shared by all of the arterial beds (Fig. 1A). 
The top 10 canonical pathways of each arterial bed in comparison to the healthy control to, as well as the top 25 
pathways from the analysis of all atherosclerotic arteries versus healthy controls are shown in Tables 3 and 4 and 
SYMBOL ACCESSION FC P FDR SYMBOL ACCESSION FC P FDR
Aorta vs carotid Carotid vs femoral
APOD NM_001647.2 43.4 2.87*10−7 7.15*10−5 HOXC6 NM_004503.3 − 17.5 2.57*10−15 3.41*10−11
CXCL14 NM_004887.3 22.3 1.04*10−10 2.15*10−7 AK123741 − 8.9 2.57*10−15 3.41*10−11
HOXC6 NM_004503.3 16.2 8.70*10−12 8.98*10−8 MMP13 NM_002427.2 − 7.5 3.77*10−9 3.33*10−6
PLA2G2A NM_000300.2 16.1 4.42*10−9 3.26*10−6 HOXC8 NM_022658.3 − 6.7 2.57*10−15 3.41*10−11
PI16 NM_153370.2 14.2 7.95*10−9 5.02*10−6 LMO3 NM_018640.3 6.5 1.13*10−9 1.16*10−6
SOST NM_025237.2 − 10.5 3.52*10−7 8.23*10−5 HOXA5 NM_019102.2 − 6.2 2.57*10−15 3.41*10−11
IL6 NM_000600.1 9.7 1.65*10−10 2.74*10−7 PITX1 NM_002653.3 − 6.0 4.88*10−14 1.89*10−10
RASD1 NM_016084.3 9.0 7.95*10−9 5.02*10−6 HOXC4 NM_014620.4 − 5.8 2.57*10−15 3.41*10−11
LOC653879 XM_936226.1 8.6 7.66*10−7 1.46*10−4 HOXA9 NM_152739.3 − 5.7 2.57*10−15 3.41*10−11
THBS4 NM_003248.3 8.6 2.61*10−10 3.62*10−7 SFRP1 NM_003012.3 5.2 1.13*10−5 1.09*10−3
HOXA5 NM_019102.2 8.4 8.70*10−12 8.98*10−8 Femoral vs aorta
C3 NM_000064.1 7.3 1.53*10−7 4.80*10−5 APOD NM_001647.2 − 27.8 2.85*10−5 9.15*10−3
DARC NM_002036.2 7.2 1.33*10−6 2.19*10−4 CXCL14 NM_004887.3 − 16.8 6.96*10−6 4.56*10−3
SCARA5 NM_173833.4 6.5 1.11*10−6 1.93*10−4 PI16 NM_153370.2 − 12.7 3.53*10−7 9.36*10−4
C4orf7 NM_152997.2 6.4 1.01*10−4 5.34*10−3 PLA2G2A NM_000300.2 − 11.5 3.91*10−6 3.46*10−3
APOLD1 NM_030817.1 6.2 8.70*10−12 8.98*10−8 SFRP1 NM_003012.3 − 11.5 5.77*10−6 4.22*10−3
SLC14A1 NM_015865.2 − 6.0 2.26*10−6 3.30*10−4 IL6 NM_000600.1 − 8.3 1.01*10−5 5.47*10−3
CD19 NM_001770.4 5.8 8.32*10−6 8.88*10−4 LOC653879 XM_936226.1 − 8.3 2.13*10−6 2.64*10−3
CD79A NM_021601.3 5.8 5.19*10−6 6.14*10−4 SPON1 NM_006108.2 − 7.3 3.95*10−5 1.04*10−2
C6 NM_000065.1 5.8 6.09*10−11 1.62*10−7 C4orf7 NM_152997.2 − 6.9 1.15*10−4 1.75*10−2
CCL19 NM_006274.2 5.5 6.22*10−8 2.34*10−5 CCL21 NM_002989.2 − 6.8 2.62*10−6 2.83*10−3
NLF2 XM_940314.2 5.5 3.24*10−9 2.76E-*10−6 CCL19 NM_006274.2 − 6.3 1.65*10−7 8.06*10−4
LOC651751 XM_940969.1 5.5 2.26*10−6 3.30*10−4 FCRLA NM_032738.3 − 6.3 3.21*10−6 3.07*10−3
FBLN1 NM_001996.2 5.5 6.22*10−8 2.34*10−5 GREM1 NM_013372.5 − 6.2 1.11*10−8 1.71*10−4
NR4A2 NM_006186.2 5.3 1.21*10−9 1.34*10−6 C3 NM_000064.1 − 6.1 3.21*10−6 3.07*10−3
SPON1 NM_006108.2 5.3 1.90*10−6 2.89*10−4 CD79A NM_001783.3 − 5.9 4.76*10−6 3.88*10−3
GREM1 NM_013372.5 5.3 3.24*10−9 2.76*10−6 SCARA5 NM_173833.4 − 5.8 5.84*10−4 3.75*10−2
C7 NM_000587.2 5.3 6.09*10−11 1.62*10−7 LOC652694 XM_942302.1 − 5.8 1.21*10−5 5.83*10−3
SVEP1 NM_153366.2 5.2 3.52*10−7 8.23*10−5 CD79A NM_021601.3 − 5.5 1.21*10−5 5.83*10−3
FOSB NM_006732.1 5.2 2.37*10−9 2.27*10−6 DARC NM_002036.2 − 5.4 5.84*10−4 3.75*10−2
LOC401845 XM_377426.1 5.0 1.76*10−5 1.55*10−3 CD19 NM_001770.4 − 5.4 3.36*10−5 9.77*10−3
LOC651751 XM_940969.1 − 5.3 1.44*10−5 6.28*10−3
ABCA8 NM_007168.2 − 5.0 6.96*10−6 4.56*10−3
Table 2.  The most significantly differentially expressed (FC ≥ ± 5, FDR < 0.05) genes between 
atherosclerotic plaques from plaques from different arterial beds (abdominal aorta, carotid, femoral). 
aAbbreviations: FC = fold changes (FC); FDR = False discovery rate.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:41483 | DOI: 10.1038/srep41483
the full list of pathways with significant differential expression is provided in Supplementary File 4. The number 
of genes up- and downregulated is shown as well as the ratio of differentially expressed genes on the pathway to 
all the genes on the pathway. Most of the pathways that showed significant (FDR < 0.05) up-regulation in ather-
osclerotic plaques were related to the inflammatory process in the arterial wall, including inflammatory markers, 
such as CD4 and CD28, as well as CXCR4. The pathways that are differentially expressed are all closely related to 
the inflammation and ensuing apoptosis of the cells of the arterial wall. The 121 pathways differentially expressed 
in all the atherosclerotic arteries are mostly related to the leukocyte activity of arterial wall, involving for example 
pathways that lead to adhesion and diapedesis of agranulocytes. Abdominal aortic plaques were found to have 
more unique differentially expressed pathways, including up-regulation of several distinct inflammatory path-
ways, whilst the 25 pathways differentially expressed only in femoral plaques included several down-regulated 
catabolic pathways (Table 4).
GO-term analyses showed that 288 Go terms were up-regulated in atherosclerotic plaques in comparison to 
controls (Supplementary File 5). Similarly to IPA pathway analysis gene sets up-regulated in individual arterial 
beds greatly overlapped (Fig. 1B) and were mostly related to inflammatory processes (Supplementary File 4). As 
with the IPA pathways, aortic plaques had the greatest number of unique differentially expressed gene sets. Only 
GO term “ncRNA metabolic process” was down-regulated in carotid plaques in comparison to controls.
Discussion
Our results underline the importance of osteopontin in the development of atherosclerosis and suggest that the 
different expression of cell death-inducing DFFA-like effector C and A may also be involved in the pathogenesis 
of atherosclerosis. These results offer more specified and wider information on the biochemical pathways dif-
ferentially expressed (against most recently updated data bases) in atherosclerotic plaques, artery type specific 
expression information and further extend and specify the previously published results. We demonstrate the 
extensively individual genes that are differentially expressed and biological pathways in atherosclerotic plaques 
using the unique sample collection of the TVS. Perisic et al.32 conducted a similar study, which yielded similar 
results, where atherosclerotic plaques were compared to blood samples from, we consider using a healthy artery 
to be a more valid method as the tissues are more alike. The differentially expressed genes and pathways reported 
here are mostly involved in the inflammatory events previously assumed to occur in the atherosclerotic arterial 
wall, i.e. the recruitment and translocation of leucocytes through the intimal layer and infiltration of the vessel 
wall, differentiation of macrophages to foam cells, and the remodeling of extracellular matrix, which affects the 
stability of the plaque.
Osteopontin was the most up-regulated gene in the atherosclerotic plaques in comparison to healthy con-
trol arteries. Ikeda et al. have previously shown atherosclerotic severity dependent expression of osteopontin in 
human aortic plaques33 and osteopontin has also been connected to coronary artery disease in a large GWAS 
study34. Osteopontin is a key component in inflammatory processes, involved in cell migration and as a che-
moattractant for monocytes35 and in adhesion in vascular and T-cells35. Our results showing the up-regulation 
of osteopontin are supported also by previous evidence that it is expressed by foam cells derived from smooth 
muscle cells33 and that it has been indicated in the calcification process of the atherosclerotic plaque. Osteopontin 
Figure 1. A Venn diagram showing the number of (A) Ingenuity Canonical Pathways and (B) GO-terms 
differentially expressed in different arterial beds and the overlapping of those pathways/GO-terms between 
atherosclerotic plaques from different arterial beds.
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has the ability to bind calcium25,36 which is presumed to be a response to prevent further mineralization of the 
plaque37. Osteopontin also participates in the recruitment and further differentiation of macrophages36, through 
this role, the expression levels of osteopontin also correlate with the plaques’ stability as the amount and subtype 
of macrophages correlate with plaque stability. Due to the wide range of effects and excessive expression in the 
plaque tissue, osteopontin is clearly one of the key players in the pathogenesis of atherosclerosis. Interferon beta 
has been shown to modulate the expression of osteopontin by Chen et al.38 in multiple sclerosis and our results 
suggest it might be an interesting pharmacological approach in atherosclerosis as well.
Also cathepsins, a group of proteinases including some collagenases and bone reabsorption associated 
enzymes, some of which are known to participate in vascular diseases39 were significantly up-regulated. Now our 
results give context and show the role of cathepsins (CTS) in relation to other differentially expressed genes as 
part of the complex process of atherosclerosis pathogenesis.
Several multiple matrix metalloproteinases (MMPs) showed very substantial up-regulation in atherosclerotic 
plaques. Our results further affirm the role of two MMPs (MMP12 and − 9) previously associated with stroke in 
GWAS analysis by the METASTROKE collaboration40, and carotid artery atherosclerosis32. MMPs are peptidases 
that have been shown to participate in vascular remodeling14 and plaque formation14 as well as in plaque rupture39 
in atherosclerotic arteries. They also have modulatory functions in cell signaling41. In our pathway analysis MMPs 
were found in canonical pathways related to adhesion and diapedesis of leukocytes, facilitating the transmigration 
of leukocytes through endothelial layer. Of the MMP family MMP7, MMP9, MMP11 and MMP12 had the high-
est up-regulation levels with different proportional levels in different arterial beds. The abundance of MMP9 in 
femoral plaques and MMP12 in carotid plaques supports the idea of MMPs expression in plaque formation being 
site-, and possibly sex-, specific42,43.
Differentially expressed lipid metabolism related genes included CIDEC, CIDEA and apolipoproteins 
E, D and C1. The up-regulation of ApoE and ApoC1 in our advanced atherosclerotic artery samples seem to 
Ingenuity Canonical Pathways
B-H 
p-value 
(FDR)a
Ratio: differentially 
expressed/all 
pathway genes
Downregulated 
genes on the 
pathway
Up-regulated 
genes on the 
pathway
Genes not 
differentially expressed 
on the pathway
Antigen Presentation Pathway 3.89*10−10 0.730 0/37 (0%) 27/37 (73%) 10/37 (27%)
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation 7.41*10
−10 0.404 21/183 (11%) 53/183 (29%) 109/183 (60%)
Dendritic Cell Maturation 7.41*10−10 0.407 14/177 (8%) 58/177 (33%) 105/177 (59%)
Crosstalk between Dendritic Cells and 
Natural Killer Cells 7.08*10
−8 0.472 6/89 (7%) 36/89 (40%) 47/89 (53%)
Leukocyte Extravasation Signaling 7.08*10−8 0.369 23/198 (12%) 50/198 (25%) 125/198 (63%)
Role of Macrophages. Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 7.94*10
−8 0.331 29/296 (10%) 69/296 (23%) 198/296 (67%)
Granulocyte Adhesion and Diapedesis 1.95*10−7 0.373 9/177 (5%) 57/177 (32%) 111/177 (63%)
Type I Diabetes Mellitus Signaling 7.24*10−7 0.418 3/110 (3%) 43/110 (39%) 64/110 (58%)
Axonal Guidance Signaling 4.17*10−6 0.288 56/434 (13%) 69/434 (16%) 309/434 (71%)
TREM1 Signaling 4.47*10−6 0.453 1/75 (1%) 33/75 (44%) 41/75 (55%)
LXR/RXR Activation 5.62*10−6 0.388 16/121 (13%) 31/121 (26%) 74/121 (61%)
Agranulocyte Adhesion and Diapedesis 1.29*10−5 0.339 17/189 (9%) 47/189 (25%) 125/189 (66%)
Communication between Innate and 
Adaptive Immune Cells 1.35*10
−5 0.416 2/89 (2%) 35/89 (39%) 52/89 (58%)
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 1.35*10
−5 0.376 6/125 (5%) 41/125 (33%) 78/125 (62%)
CD28 Signaling in T Helper Cells 1.35*10−5 0.381 7/118 (6%) 38/118 (32%) 73/118 (62%)
Role of NFAT in Regulation of the Immune 
Response 1.35*10
−5 0.345 14/171 (8%) 45/171 (26%) 112/171 (65%)
LPS/IL-1 Mediated Inhibition of RXR 
Function 2.09*10
−5 0.321 29/221 (13%) 42/221 (19%) 150/221 (68%)
Graft-versus-Host Disease Signaling 2.19*10−5 0.500 1/48 (2%) 23/48 (48%) 24/48 (50%)
CTLA4 Signaling in Cytotoxic T 
Lymphocytes 7.08*10
−5 0.398 6/88 (7%) 29/88 (33%) 53/88 (60%)
NF-Î°B Signaling 7.08*10−5 0.331 16/172 (9%) 41/172 (24%) 115/172 (67%)
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 7.08*10
−5 0.328 16/180 (9%) 43/180 (24%) 121/180 (67%)
ILK Signaling 8.13*10−5 0.324 35/185 (19%) 25/185 (14%) 125/185 (68%)
FcÎ3 Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 8.91*10
−5 0.387 7/93 (8%) 29/93 (31%) 57/93 (61%)
Integrin Signaling 1.02*10−4 0.314 30/207 (14%) 35/207 (17%) 142/207 (69%)
Complement System 1.38*10−4 0.514 4/37 (11%) 15/37 (41%) 18/37 (49%)
Table 3.  Top 25 pathways differentially expressed in advanced atherosclerotic plaques when compared to 
the healthy left internal thoracic artery (LITA). ap-value calculated with Benjamini-Hochberg method.
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support the correlations that have been found with lipid deposits and cholesterol accumulation44 and plaque 
size45. Interestingly, in our study we also showed that ApoD was down-regulated in the plaque tissue. CIDEC and 
CIDEA have previously been associated with the intake of lipids and formation of lipid droplets in macrophage 
derived foam cells46. Therefore, their down-regulation may indicate decreased foam cell formation in advanced 
atherosclerotic plaques or possibly other currently unknown roles in the atherosclerotic plaque47.
Several chemokines, as well as their receptors, were up-regulated, the most important ones being CCL5 and 
CCL2. These have been shown to be involved in chemokinesis, dendritic cell signaling48, monocyte recruitment49 
and enhancement of vascular permeability, all of which fit the pathology of atherosclerosis and have been associ-
ated with several pathological conditions50, including, but not limited to, atherosclerosis50.
From our results we can speculate that the genes differently expressed in plaques from different arterial beds 
might help to explain as to why certain plaques tend to be more stable and calcify or become fibrotic. The delay to 
surgery is shorter in carotid surgery, as opposed to femoral artery or abdominal aorta, because they often contain 
an unstable plaque and are highly symptomatic. This is likely to explain a part of the different expression patterns 
in the carotid plaques. As the carotid plaques are more frequently unstable the role of MMP12 and − 7 might war-
rant further research, as our results show that of all the arterial beds these MMPs have the greatest expression in 
Ingenuity Canonical Pathways
B-H 
p-value 
(FDR)
Ratio: differentially 
expressed/all 
pathway genes
Downregulated 
genes on the 
pathway
Up-regulated 
genes on the 
pathway
Genes not 
differentially expressed 
on the pathway
Aortic vs LITA
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation 5.01*10
−13 0.470 23/183 (13%) 63/183 (34%) 97/183 (53%)
Dendritic Cell Maturation 1.00*10−12 0.469 15/177 (8%) 68/177 (38%) 94/177 (53%)
Role of Macrophages. Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 3.89*10
−10 0.382 32/296 (11%) 81/296 (27%) 183/296 (62%)
Granulocyte Adhesion and Diapedesis 1.74*10−9 0.429 8/177 (5%) 68/177 (38%) 101/177 (57%)
Crosstalk between Dendritic Cells and 
Natural Killer Cells 2.00*10
−9 0.528 6/89 (7%) 41/89 (46%) 42/89 (47%)
Leukocyte Extravasation Signaling 1.32*10−8 0.404 21/198 (11%) 59/198 (30%) 118/198 (60%)
Axonal Guidance Signaling 1.66*10−8 0.334 64/434 (15%) 81/434 (19%) 289/434 (67%)
Type I Diabetes Mellitus Signaling 2.29*10−8 0.473 3/110 (3%) 49/110 (45%) 58/110 (53%)
Antigen Presentation Pathway 5.62*10−8 0.676 0/37 (0%) 25/37 (68%) 12/37 (32%)
TREM1 Signaling 9.33*10−8 0.520 1/75 (1%) 38/75 (51%) 36/75 (48%)
Carotid vs LITA
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation 3.31*10
−10 0.432 25/183 (14%) 54/183 (30%) 104/183 (57%)
Dendritic Cell Maturation 5.75*10−9 0.418 16/177 (9%) 58/177 (33%) 103/177 (58%)
Axonal Guidance Signaling 1.86*10−7 0.320 61/434 (14%) 78/434 (18%) 295/434 (68%)
Granulocyte Adhesion and Diapedesis 1.86*10−7 0.395 11/177 (6%) 59/177 (33%) 107/177 (60%)
Crosstalk between Dendritic Cells and 
Natural Killer Cells 1.86*10
−7 0.483 6/89 (7%) 37/89 (42%) 46/89 (52%)
Antigen Presentation Pathway 3.16*10−7 0.649 0/37 (0%) 24/37 (65%) 13/37 (35%)
Leukocyte Extravasation Signaling 6.76*10−7 0.374 23/198 (12%) 51/198 (26%) 124/198 (63%)
TREM1 Signaling 7.59*10−7 0.493 1/75 (1%) 36/75 (48%) 38/75 (51%)
Agranulocyte Adhesion and Diapedesis 4.90*10−6 0.365 19/189 (10%) 50/189 (26%) 120/189 (63%)
Role of Macrophages. Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 6.03*10
−6 0.328 29/296 (10%) 68/296 (23%) 199/296 (67%)
Femoral vs LITA
Leukocyte Extravasation Signaling 3.98*10−11 0.404 26/198 (13%) 54/198 (27%) 118/198 (60%)
Hepatic Fibrosis/Hepatic Stellate Cell 
Activation 1.48*10
−10 0.404 20/183 (11%) 54/183 (30%) 109/183 (60%)
Dendritic Cell Maturation 1.48*10−10 0.407 15/177 (8%) 57/177 (32%) 105/177 (59%)
Antigen Presentation Pathway 4.57*10−8 0.649 0/37 (0%) 24/37 (65%) 13/37 (35%)
Role of Macrophages. Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 8.13*10
−8 0.324 28/296 (9%) 68/296 (23%) 200/296 (68%)
Granulocyte Adhesion and Diapedesis 1.58*10−7 0.367 7/177 (4%) 58/177 (33%) 112/177 (63%)
TREM1 Signaling 1.62*10−7 0.48 1/75 (1%) 35/75 (47%) 39/75 (52%)
Crosstalk between Dendritic Cells and 
Natural Killer Cells 2.88*10
−6 0.427 6/89 (7%) 32/89 (36%) 51/89 (57%)
Integrin Signaling 3.24*10−6 0.333 33/207 (16%) 36/207 (17%) 138/207 (67%)
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 3.55*10
−6 0.344 19/180 (11%) 43/180 (24%) 118/180 (66%)
Table 4.  Top 10 differentially expressed canonical pathways from atherosclerotic plaques from different 
arterial beds (abdominal aorta, carotid, femoral) in comparison to left internal thoracic artery controls.
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carotid artery samples. Also, our results suggest the role of homeobox-genes as stabilizing elements because two 
homeobox genes, HOXC6 and HOXA5 (Table 2), were the significantly down-regulated genes in carotid artery as 
opposed to the femoral artery and abdominal aorta.
Our pathway analysis results are well in line with previous analysis done with smaller sample sets or with 
those deduced from GWAS results. When comparing IPA pathways enriched with genes associated with CAD34 
or large artery stroke51 in GWAS, our data indicated 44 pathways out of the 96 pathways connected with CAD 
were differentially expressed and 11 pathways out of the 16 connected with large artery stroke17. Moreover 12 out 
of the 16 pathways previously connected to large artery stroke were differentially expressed in carotid plaques in 
comparison to controls17. The GO terms with significant different expression are also very similar to those found 
by Nai et al.16. Although their analysis contained only carotid plaques and they used different control material - 
the healthy arteries obtained near the plaques -the pathways identified in their study well match our results. In 
addition, 9 of the 10 most up-regulated GO terms in their study are up-regulated also in our data, and although 
“cytokine production” is not up-regulated in our results, “regulation of cytokine production” is ref. 16. Similar GO 
terms have also been shown to be enriched in the study conducted by Perisic et al.32.
Our pathway analysis highlights the importance of inflammation related pathways also in advanced athero-
sclerotic plaques. The pathways activated show that the movement and attachment of leukocytes is a crucial part 
of the pathogenesis of atherosclerosis. Also the remodeling of extracellular matrix and differentiation of cells 
producing extracellular components were activated, such as the pathway of hepatic stellate cell activation. The GO 
term search further affirmed the results of the inflammatory nature of atherosclerosis, as many of the GO terms 
were inflammation related. Our results also show that similar pathways are differentially expressed in peripheral 
atherosclerotic plaques from different locations, but abdominal aortic plaques have more inflammatory pathways 
up-regulated and down-regulation of several catabolic pathways can only be seen in femoral plaques.
Limitations of the study. The different hemodynamics associated with plaque localization on the arterial 
wall might have contributed to the results, along with the fact that controls had coronary artery disease, which 
implies similar systemic factors. In our study we used the LITA samples as control, as LITA is usually quite 
impervious to atherosclerosis52, and is therefore widely used as a control material in similar studies. Control 
samples from corresponding arterial beds free of atherosclerosis and from healthy subjects without systemic 
risk factors could have provided more precise analysis. However, due to ethical reasons we were not able to 
obtain such samples. In endarterectomy, intima mainly containing the plaque and inner media are removed. In 
non-atherosclerotic LITA control arteries, it is not feasible to remove the adventitia and outer media. Due to this 
setting, the LITA samples include the thin adventitia consisting mainly of loose connective tissue, whilst plaque 
samples lack the adventitial layer. This should not reduce the validity or hamper interpretation of our results. The 
suitability of LITAs as controls16 is further supported by our results being well in line with the Gene ontology 
results performed with carotid plaques and adjacent healthy tissues as controls by Perisic et al.32. In addition, we 
have previously shown that the tissue morphology is similar in LITA samples, healthy carotid artery, and abdom-
inal aorta and verified the similar expression patterns of focal adhesion molecules in these healthy arterial beds53.
Both cases and controls had similar prevalence of statin users, with 87.5% of cases and 73.5% of controls 
(Supplementary File 1) and we therefore consider the groups comparable. High rate of statin usage may have 
some effect on gene expression but does not explain the differences between cases and controls. However, it is 
noteworthy that we cannot separate the changes in gene expression caused by the pathological state from those 
caused by statins or other medication. As majority of the samples were advanced atherosclerotic plaques, more 
research is needed to determine the dominant genes and pathways active in more early phases of the pathogenesis 
of atherosclerosis. We do not use qRT-PCR to further affirm our results as it has been shown by Raitoharju et al.23 
that when FC > 3 the specificity is 100% and when FC > 1.5 it is 73.7%.
In conclusion, the development of atherosclerotic plaque extensively disturbs the function of the human arte-
rial wall and leads to different expression of a multitude of genes and pathways. Our gene expression analysis from 
human peripheral atherosclerotic plaques confirm the previous associations of many differentially expressed gene 
families, such as matrix metalloproteinases, apolipoproteins and cholesterol related receptors. Also, the role of 
osteopontin as one of the central genes in atherosclerosis was underlined in our results, as it was the single gene 
with the greatest fold change in our samples, possibly having a role in the calcification process and progression of 
atherosclerotic plaques. We also report for the first time the down-regulation of ApoD in human atherosclerotic 
plaques, and although its association with atherosclerosis is indisputable its role is still not completely under-
stood. The inflammatory nature of the disease was further supported here, as many inflammatory pathways were 
differentially expressed in the advanced peripheral atherosclerotic plaques. As seen in Fig. 1, atherosclerosis has 
significant differences in gene expression depending on the site of the arterial plaque, and only 50.4% of IPA path-
ways and 41.2% of GO terms are in common between all atherosclerosis affected arteries. These results will serve 
as a good map for further research on the genes and pathways behind human atherosclerosis.
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